131I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma
Top Cited Papers
- 3 February 2005
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 352 (5), 441-449
- https://doi.org/10.1056/nejmoa041511
Abstract
Advanced-stage follicular B-cell lymphoma is considered incurable. Anti-CD20 radioimmunotherapy is effective in patients who have had a relapse after chemotherapy or who have refractory follicular lymphoma, but it has not been tested in previously untreated patients.Keywords
This publication has 24 references indexed in Scilit:
- A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911Blood, 2003
- The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomabSeminars in Oncology, 2003
- Treatment-Related Myelodysplasia and Acute Leukemia in Non-Hodgkin’s Lymphoma PatientsJournal of Clinical Oncology, 2003
- Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphomaBlood, 2002
- Radioimmunotherapy with Iodine-131 Tositumomab in Patients with Low-Grade Non-Hodgkin's B-Cell Lymphoma Does Not Induce Loss of Acquired Humoral Immunity against Common AntigensClinical Immunology, 2001
- Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluationBlood, 2001
- Recombinant Interferon Alfa-2b Combined with a Regimen Containing Doxorubicin in Patients with Advanced Follicular LymphomaNew England Journal of Medicine, 1993
- Radioimmunotherapy of B-Cell Lymphoma with [131I]Anti-B1 (Anti-CD20) AntibodyNew England Journal of Medicine, 1993
- Stage I and II non-hodgkin's lymphomas: Long-term results of radiation therapyInternational Journal of Radiation Oncology*Biology*Physics, 1989
- Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytesEuropean Journal of Immunology, 1986